Preliminary Clinical Trial Data From CSL's A/H1N1 Vaccine Inconclusive, But Distribution Plans Underway
This article was originally published in PharmAsia News
Executive Summary
PERTH, Australia - Australia's CSL released preliminary data from adult clinical trials of its Panvax vaccine, but the results were inconclusive and additional data is expected in coming weeks, according to Australia's Commonwealth Chief Medical Officer Jim Bishop
You may also be interested in...
Australia's CSL Gets TGA Green Light For Swine Flu Vaccine; Donates 10 Percent Of Supply To WHO
PERTH, Australia - One week after CSL announced that one dose of its swine flu vaccine Panvax was effective in staving off the A/H1N1 virus, the company received the green light from Australia's Therapeutic Goods Administration to register the product in Australia for use in people older than 10 years of age
Australia's CSL Gets TGA Green Light For Swine Flu Vaccine; Donates 10 Percent Of Supply To WHO
PERTH, Australia - One week after CSL announced that one dose of its swine flu vaccine Panvax was effective in staving off the A/H1N1 virus, the company received the green light from Australia's Therapeutic Goods Administration to register the product in Australia for use in people older than 10 years of age
CSL Announces Robust Immune Response From Single Dose Of Swine Flu Vaccine; TGA Approval Expected Soon
PERTH, Australia - CSL Limited announced Sept. 11 that 95 percent of swine flu vaccine clinical trial participants achieved appropriate antibody levels with a single 15 mcg dose of the new Panvax vaccine